Home › Metastatic Cancer › Pennsylvania › Lancaster
Metastatic Cancer clinical trials in Lancaster, PA
4 studies for Metastatic Cancer are looking for participants at sites in and around Lancaster (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RecruitingPhase 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RecruitingPhase 1
- Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute, Lancaster
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RecruitingPhase 3
- Research Site, Lancaster
Metastatic Cancer trials in other cities
- Houston, TX104 studies
- New York City, NY93 studies
- Nashville, TN70 studies
- Boston, MA63 studies
- Los Angeles, CA57 studies
- St. Louis, MO54 studies
- Arlington, VA53 studies
- Philadelphia, PA46 studies
- Chicago, IL45 studies
- San Antonio, TX44 studies
- Washington, DC43 studies
- Dallas, TX42 studies
Other studies in Lancaster
- Non-Small Cell Lung Cancer7 studies
- Cardiovascular Disease5 studies
- Heart Failure5 studies
- Breast Cancer4 studies
- Prostate Cancer4 studies
- Lung Cancer3 studies
- Amblyopia3 studies
- Heart Diseases3 studies
- Bladder Cancer3 studies
- Non-Muscle Invasive Bladder Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.